9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity

Cardiovascular and central nervous system (CNS) toxins account for some of the most critical resuscitations encountered by emergency medicine pharmacists. Digoxin, tricyclic antidepressants (TCAs), and antimuscarinic agents each present distinct toxicologic profiles with overlapping features—such as conduction delays, dysrhythmias, and altered mental status—yet their antidote indications, cellular targets, and pharmacotherapeutic rescue strategies diverge significantly. Mastery of these specialized poisonings requires immediate recognition of electrophysiologic hallmarks, precise dosing calculations under physiological crisis, and rigorous vigilance against hazardous drug-drug and drug-disease contraindications.

---

Digoxin Toxicity: Molecular Mechanisms & Clinical Presentations

Digoxin is a cardiac glycoside that exerts positive inotropic and negative dromotropic effects through selective inhibition of the myocardial sarcolemmal $\text{Na}^+/\text{K}^+\text{-ATPase}$ pump. At therapeutic levels, this inhibition increases intracellular sodium, which diminishes the trans-sarcolemmal sodium gradient and reduces calcium extrusion via the $\text{Na}^+/\text{Ca}^{2+}$ exchanger (NCX). The resulting accumulation of intracellular calcium within the sarcoplasmic reticulum augments myocardial contractility while concurrently increasing vagal parasympathetic tone at the sinoatrial (SA) and atrioventricular (AV) nodes.

In toxic states, excessive intracellular calcium accumulation triggers delayed afterdepolarizations (DADs), producing triggered automaticity, severe ectopy, and life-threatening ventricular tachyarrhythmias. Concurrently, excessive vagal stimulation and direct nodal inhibition precipitate profound conduction block.

Acute vs. Chronic Digoxin Toxicity

The clinical presentation, laboratory abnormalities, and prognostic markers differ markedly between acute overdose and chronic accumulation:

Digitalis-Induced Dysrhythmias

Digoxin toxicity can provoke virtually any cardiac rhythm disturbance. The hallmark pathophysiologic combination is increased automaticity coupled with impaired AV conduction:

1. Ventricular Ectopy & Dysrhythmias: Frequent premature ventricular contractions (PVCs), often presenting as ventricular bigeminy or trigeminy; bidirectional ventricular tachycardia (alternating frontal plane QRS axis from beat to beat), which is virtually pathognomonic for digitalis poisoning; polymorphic or monomorphic ventricular tachycardia; ventricular fibrillation.
2. Conduction Delays & Bradyarrhythmias: Severe sinus bradycardia, sinus arrest, first-degree AV block, high-grade second-degree AV block (Mobitz I or II), and complete (third-degree) heart block.
3. Supraventricular Dysrhythmias: Paroxysmal atrial tachycardia (PAT) with 2:1 block (classic digitalis dysrhythmia; increased atrial automaticity with AV nodal conduction delay); slow atrial fibrillation with an unnaturally regular ventricular response (junctional escape rhythm indicating complete heart block).

---

Digoxin-Specific Antibody Fragments (DigiFab)

Digoxin-specific Fab fragments (DigiFab, ovine) consist of sterile, purified, lyophilized monovalent Fab immunoglobulin fragments derived from sheep immunized with a digoxin-albumin conjugate. Papain enzymatic cleavage removes the Fc constant region, preventing complement activation, reducing immunogenicity, and facilitating rapid renal elimination.

Mechanism of Action

Each vial of DigiFab (40 mg) contains purified Fab fragments with a molecular weight of approximately 46,000 Daltons. Monovalent Fab fragments bind free intravascular digoxin with an affinity constant ($K_a \approx 10^9\text{ to }10^{10}\text{ M}^{-1}$) that is significantly higher than the affinity of digoxin for $\text{Na}^+/\text{K}^+\text{-ATPase}$. Once bound, the Fab-digoxin complex is pharmacologically inert and cleared renally via glomerular filtration (elimination half-life ~15 to 20 hours in normal renal function).

Clinical Indications for DigiFab

1. Cardiac arrest secondary to digitalis toxicity or life-threatening ventricular dysrhythmias (bidirectional VT, VT, VF).
2. Hemodynamically unstable bradyarrhythmias refractory to atropine (severe sinus bradycardia, second-degree or third-degree AV block).
3. Serum potassium $>5.0\text{ mEq/L}$ in acute digitalis poisoning (independent of serum digoxin level or rhythm).
4. Ingestion of $>10\text{ mg}$ of digoxin in healthy adults ($>4\text{ mg}$ or $>0.1\text{ mg/kg}$ in children).
5. Steady-state serum digoxin concentration $>10\text{ to }15\text{ ng/mL}$ in acute poisoning or $>2.0\text{ to }3.0\text{ ng/mL}$ in chronic accumulation accompanied by progressive end-organ toxicity.

DigiFab Dosing Calculations & Formulas

Each 40 mg vial of DigiFab binds approximately 0.5 mg (500 mcg) of digoxin (or digitoxin).

Loading diagram...

1. Calculation Based on Steady-State Serum Digoxin Concentration

When a steady-state serum concentration (drawn at least 6 to 8 hours post-dose to allow complete tissue distribution) is known:

$\text{Number of Vials} = \frac{\text{Serum Digoxin (ng/mL)} \times \text{Patient Weight (kg)}}{100}$

Worked Clinical Example: A 70-kg patient with chronic toxicity presents with AV dissociation and a steady-state serum digoxin level of 8.0 ng/mL:

$\text{Number of Vials} = \frac{8.0\text{ ng/mL} \times 70\text{ kg}}{100} = \frac{560}{100} = 5.6 \approx 6\text{ vials}$

2. Calculation Based on Known Ingested Amount

When the ingested amount of digoxin is known, assuming 80% systemic bioavailability for oral tablets:

$\text{Total Body Burden (mg)} = \text{Dose Ingested (mg)} \times 0.80$ $\text{Number of Vials} = \frac{\text{Total Body Burden (mg)}}{0.5\text{ mg bound per vial}}$

Worked Clinical Example: A patient ingests 20 tablets of 0.25 mg digoxin (5 mg total):

$\text{Body Burden} = 5.0\text{ mg} \times 0.80 = 4.0\text{ mg}$ $\text{Number of Vials} = \frac{4.0\text{ mg}}{0.5\text{ mg/vial}} = 8\text{ vials}$

3. Empiric Dosing Protocols (When Levels and Amounts Are Unknown)

• Acute Overdose with Instability / Cardiac Arrest: Administer 10 to 20 vials IV. In cardiac arrest, administer by rapid IV push. Twenty vials binds 10 mg of digoxin, which neutralizes a massive, lethal overdose.
• Chronic Ingestion with Life-Threatening Toxicity: Administer 3 to 6 vials IV (infused over 30 minutes in stable patients). In chronic toxicity, total body distribution is vast, and smaller initial doses (1 to 2 vials) often reverse toxicity without precipitating sudden rebound heart failure or hypokalemia.

Post-DigiFab Monitoring & Critical Pitfalls

1. Total Digoxin Assays Are Uninterpretable: Commercial clinical laboratory digoxin immunoassays cannot distinguish between pharmacologically active free digoxin and inactive Fab-bound digoxin complexes. Following DigiFab administration, measured total serum digoxin concentrations will falsely surge to >10-fold baseline and remain elevated for 1 to 2 weeks (or longer in renal failure). Clinicians must follow clinical status, heart rate, and 12-lead ECG, NOT repeat total serum levels.
2. Hypokalemia: As DigiFab strips digoxin from myocardial and skeletal muscle $\text{Na}^+/\text{K}^+\text{-ATPase}$ pumps, cellular potassium re-uptake occurs rapidly. Monitor serum potassium every 1 to 2 hours initially; treat hypokalemia aggressively to prevent secondary dysrhythmias.
3. Decompensation of Underlying Heart Failure or Rapid Atrial Fibrillation: Rapid neutralization of digoxin abruptly removes inotropic support and eliminates AV nodal brake, potentially precipitating pulmonary edema or rapid ventricular response.

---

Tricyclic Antidepressant (TCA) Toxicity

Tricyclic antidepressants (amitriptyline, nortriptyline, imipramine, doxepin, clomipramine) are among the most lethal prescription ingestions. Life-threatening toxicity stems from simultaneous antagonism across four critical receptor systems:

1. Myocardial Fast Sodium Channel Blockade (Phase 0 $\text{I}_{\text{Na}}$): Class IA antiarrhythmic effect. Slows depolarization, widens the QRS complex, prolongs the PR and QTc intervals, and induces terminal rightward axis deviation.
2. Peripheral Alpha-1 Adrenergic Blockade: Induces refractory peripheral vasodilation and severe distributive shock.
3. Central and Peripheral Muscarinic ($M_1, M_2$) Blockade: Triggers the anticholinergic toxidrome (sinus tachycardia, mydriasis, hyperthermia, dry skin, delirium, urinary retention, bowel hypomotility).
4. Central $\text{GABA}_{\text{A}}$ Receptor Antagonism: Provokes intractable central nervous system excitation, seizures, and status epilepticus.

                         ELECTROCARDIOGRAPHIC PREDICTORS IN TCA OVERDOSE
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ QRS Duration < 100 ms: Low risk of seizures or dysrhythmias                  │
  │ QRS Duration > 100 ms: ~34% Risk of Seizures                                │
  │ QRS Duration > 160 ms: ~50% Risk of Life-Threatening Ventricular Dysrhythmias│
  │ Terminal Rightward Axis (Lead aVR): R wave > 3 mm OR R/S ratio > 0.7        │
  └─────────────────────────────────────────────────────────────────────────────┘

Electrocardiographic Risk Stratification

• QRS $>100\text{ ms}$: Strongly predicts impending generalized seizures (34% risk). Mandates immediate intravenous sodium bicarbonate therapy.
• QRS $>160\text{ ms}$: Strongly predicts impending life-threatening ventricular dysrhythmias (monomorphic/polymorphic VT, ventricular fibrillation; 50% risk).
• Terminal 40-ms Rightward Frontal Axis Shift in Lead aVR: Selective blockade of the right bundle branch results in a prominent terminal $R\text{ wave} > 3\text{ mm}$ in lead aVR, or an $R/S\text{ ratio} > 0.7$ in aVR. This sign is highly sensitive for sodium channel blocker toxicity.

Sodium Bicarbonate Therapy: Protocols & Dual Molecular Mechanisms

Sodium bicarbonate (8.4% hypertonic solution, 1 mEq/mL; 50 mEq per 50 mL ampule) is the definitive, life-saving antidote for TCA cardiotoxicity.

• Initial Resuscitation Bolus: 1 to 2 mEq/kg IV push (typically 1 to 2 ampules [50 to 100 mEq] administered over 1 to 2 minutes).
• Repeat Titration: Repeat the 1 to 2 mEq/kg bolus every 3 to 5 minutes until the QRS complex narrows to $<100\text{ ms}$ and systemic arterial hypotension improves.
• Continuous Maintenance Infusion: Once initial QRS narrowing is achieved, initiate a continuous IV infusion mixed as 150 mEq sodium bicarbonate (3 ampules) in 1,000 mL of 5% Dextrose in Water ($\text{D}_5\text{W}$) (yielding a nearly isotonic solution of ~300 mOsm/L). Infuse at 150 to 250 mL/h (2 to 3 times the maintenance fluid rate).
• Therapeutic Targets & Discontinuation Rules: Target a systemic arterial pH of 7.45 to 7.55 and serum sodium of 150 to 155 mEq/L. Stop or titrate down the infusion if arterial pH exceeds 7.55 or serum sodium exceeds 155 mEq/L to prevent severe metabolic alkalosis, hypokalemic tetany, and hypernatremia.

The Dual Mechanism of Action

1. Hypertonic Sodium Load: Infusing hypertonic sodium increases extracellular sodium concentration, steepening the electrochemical concentration gradient across the myocardial cell membrane. This passive electrochemical force overcomes the competitive drug blockade at the voltage-gated fast sodium channels.
2. Serum Alkalinization (pH 7.45–7.55): TCAs are weak bases with a $\text{p}K_a$ between 8.5 and 9.5. Elevating extracellular pH shifts the chemical equilibrium toward the non-ionized (uncharged, neutral) lipophilic state. The non-ionized TCA has a dramatically lower binding affinity for the neutral open/inactivated conformation of myocardial sodium channels, accelerating dissociation of the drug from the receptor.

Refractory TCA Cardiotoxicity Management

• Refractory Hypotension: First-line vasopressor is norepinephrine (direct alpha-1 agonist that overcomes competitive blockade and restores systemic vascular resistance). Avoid indirect-acting agents like dopamine, which depend on depleted endogenous catecholamine stores.
• Antiarrhythmic Drug Selection: Class IA (procainamide, quinidine), Class IC (flecainide, propafenone), and Class III (amiodarone, sotalol) antiarrhythmics are STRICTLY CONTRAINDICATED. Class IA and IC agents exacerbate sodium channel blockade, while Class III agents worsen QTc prolongation and precipitate torsades de pointes. If a ventricular dysrhythmia is refractory to sodium bicarbonate, lidocaine (Class IB, 1 to 1.5 mg/kg IV push) is the only safe antiarrhythmic because of its rapid channel on-off binding kinetics.
• Rescue Therapy: In refractory arrest or shock, administer Intravenous Lipid Emulsion (ILE 20%): 1.5 mL/kg IV bolus over 2 to 3 minutes, followed by 0.25 mL/kg/min infusion. Consider emergent venoarterial extracorporeal membrane oxygenation (VA-ECMO).

---

Anticholinergic Toxidrome & Physostigmine

The anticholinergic (antimuscarinic) toxidrome results from competitive antagonism of acetylcholine at central and peripheral muscarinic ($M_1\text{--}M_5$) receptors. Common causative agents include first-generation antihistamines (diphenhydramine, hydroxyzine), antiparkinsonian agents (trihexyphenidyl, benztropine), antispasmodics (oxybutynin, dicyclomine), belladonna alkaloids (atropine, scopolamine), and toxic plants (Datura stramonium [jimsonweed], Atropa belladonna).

Clinical Manifestations

• "Blind as a bat": Pupillary mydriasis with loss of accommodation and cycloplegia; blurred vision.
• "Dry as a bone": Complete anhidrosis, parched oral mucous membranes, dry axillae.
• "Red as a beet": Cutaneous vasodilation and flushing, predominantly over the face and upper torso.
• "Hot as a hare": Hyperthermia, driven by loss of evaporative diaphoresis and central thermoregulatory resetting.
• "Mad as a hatter": Anticholinergic delirium, agitation, visual and auditory hallucinations, mumbling speech, "phantom picking" (carphologia), and fluctuating stupor.
• "Full as a flask": Acute urinary retention and severe bladder distension; hypoactive or absent bowel sounds.
• Sinus Tachycardia: The earliest, most sensitive, and most consistent physiological marker of muscarinic blockade.

Physostigmine Salicylate: Pharmacology & Dosing

Physostigmine is a naturally occurring tertiary amine alkaloid extracted from the Calabar bean (Physostigma venenosum).

• Mechanism: Reversibly carbamylates and inhibits acetylcholinesterase, preventing the breakdown of acetylcholine. Unlike quaternary amine inhibitors (neostigmine, pyridostigmine, edrophonium), physostigmine readily crosses the blood-brain barrier because its tertiary amine structure is lipophilic, effectively reversing both central delirium and peripheral muscarinic signs.
• Dosing & Administration: 0.5 to 2.0 mg IV (pediatrics: 0.02 mg/kg, maximum single dose 0.5 mg) administered as a slow IV infusion over at least 5 minutes. Rapid push can induce severe bradycardia, hypersalivation, and seizures. If clinical response is partial, the dose may be repeated after 10 to 15 minutes.
• Bedside Safety Requirement: Atropine (1 to 2 mg IV) must be immediately drawn up and present at the bedside before administering physostigmine to treat any iatrogenic cholinergic crisis (bradycardia, severe bronchorrhea).

Strict Contraindications to Physostigmine

1. Known or Suspected Tricyclic Antidepressant Overdose: Historically, administering physostigmine in TCA overdoses caused sudden, intractable complete heart block, asystole, and fatal cardiac arrest. TCAs already impair cardiac conduction; sudden cholinergic surge further depresses SA and AV nodal pacemakers.
2. Electrocardiographic Conduction Delays: Any patient with QRS prolongation ($>100\text{ ms}$), PR prolongation, second- or third-degree AV block, or intraventricular conduction defects.
3. Severe Reactive Airway Disease: Asthma or severe COPD (cholinergic bronchospasm and hypersecretion).
4. Mechanical Obstruction: Intestinal or urinary bladder mechanical obstruction.

---

Toxicology Reference Matrix: Antidotes & Protocols